Trials / Recruiting

RecruitingNCT03568630

Blood Markers of Early Pancreas Cancer

A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer

Status: Recruiting
Phase: —
Study type: Observational
Enrollment: 1,250 (estimated)

Sponsor: University of Nebraska · Academic / Other
Sex: All
Age: 19 Years
Healthy volunteers: Accepted

Summary

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Detailed description

Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) have only an 10% chance of surviving 5 years after diagnosis. Most PDAC is advanced and not amenable to curative therapies at the time of diagnosis, owing to lack of symptoms in early disease, nonspecific symptoms when they do develop resulting in a delay in diagnosis. Identifying biomarkers of early PDAC could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of participants at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens. Participants will include individuals with family history of pancreas cancer, individuals with cystic pancreas lesions or chronic pancreatitis, and individuals with new-onset diabetes. Identifying specific biomarkers - blood markers and/or a clinical "prodrome" - in participants who go on to develop PDAC could improve the diagnostic approach outcomes for patients diagnosed with PDAC.

Conditions

Timeline

Start date: 2018-07-26
Primary completion: 2028-07-01
Completion: 2028-07-01
First posted: 2018-06-26
Last updated: 2026-02-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03568630. Inclusion in this directory is not an endorsement.